FrancophonIA/ELRC3.0 huggingface dataset:
English: Further evaluations which did show statistical significance (p<0.05) in favour of Xolair included reductions in severe exacerbations (where patient's lung function was reduced to below 60% of personal best and requiring systemic corticosteroids) and asthma-related emergency visits (comprised of hospitalisations, emergency room, and unscheduled doctor visits), and improvements in Physician's overall assessment of treatment effectiveness, Asthma-related Quality of Life (AQL), asthma symptoms and lung function.
Slovenian: Drugi izračunani parametri, ki so pokazali statistično značilnost (p<0,05) v korist zdravila Xolair, so bili zmanjšanje težkih eksacerbacij (pri katerih se je funkcija bolnikovih pljuč zmanjšala pod 60 % njegove osebne najboljše funkcije in so bili potrebni sistemski kortikosteroidi) in z astmo povezanih nujnih pregledov (sestavljeni iz sprejemov v bolnišnico, pregledov na urgenci in nenaročenih obiskov pri zdravniku) ter izboljšanje zdravnikove celotne ocene učinkovitosti zdravljenja, “z astmo povezane kvalitete življenja (AQL)”, simptomov astme in pljučne funkcije.
English: Omalizumab has been associated with age-dependent decreases in blood platelets in non-human primates, with a greater relative sensitivity in juvenile animals (see section 5.3).
Slovenian: Omalizumab povezujejo z znižanji koncentracije trombocitov pri primatih, razen pri človeku, ki so odvisna od starosti; občutljivost zanje je pri mladih živalih razmeroma večja (glejte poglavje 5.3).
English: No studies have been performed in children under 12 years.
Slovenian: Pri otrocih, ki so bili stari manj kot 12 let, niso izvedli nobenih študij.
English: However, if considered appropriate by their doctor, a caregiver may give them their Xolair injection after proper training.
Slovenian: Če pa njihov zdravnik meni, da bi bilo to primerno, jim lahko zdravilo Xolair daje njihov negovalec po tem, ko se za to ustrezno usposobi.
English: Following a single subcutaneous dose in adult and adolescent patients with asthma, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 7-8 days.
Slovenian: Po enem samem subkutanem odmerku pri odraslih in adolescentnih bolnikih z astmo se je omalizumab absorbiral počasi in dosegel najvišje serumske koncentracije čez povprečno 7-8 dni.
English: The apparent volume of distribution in patients following subcutaneous administration was 78 ± 32 ml/kg.
Slovenian: Navidezni porazdelitveni prostor pri bolnikih po subkutani aplikaciji je bil 78 ± 32 ml/kg.
English: If the wings are touched, the syringe guard may be activated too early.
Slovenian: Z dotikom teh sponk lahko namreč prezgodaj aktivirate zapiralo brizge.
English: Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section 4.2).
Slovenian: Zdravljenje z zdravilom Xolair pride v poštev samo za bolnike s prepričljivo astmo, v katero je vpleten IgE (imunoglobulin E) (glejte poglavje 4.2).
English: Prior to administration of the initial dose, patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment.
Slovenian: Pred aplikacijo prvega odmerka je treba bolnikom za določitev njihovega odmerka določiti raven IgE z enim od komercialnih kompletov za določanje celotnega IgE v serumu.
English: • Alcohol swab.
Slovenian: • alkoholni zloženec
English: Table 1 Conversion from dose to number of syringes, number of injections and total injection volume for each administration
Slovenian: Preglednica 1 Preračunavanje odmerkov v število injekcijskih brizg, v število injekcij in celotni injicirani volumen za vsako apliciranje zdravila
English: In clinical studies Xolair was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short-acting and long-acting beta agonists, leukotriene modifiers, theophyllines and oral antihistamines.
Slovenian: V kliničnih študijah so zdravilo Xolair pogosto uporabljali skupaj z inhalacijskimi in peroralnimi kortikosteroidi, kratkotrajno in dolgotrajno delujočimi agonisti adrenergičnih receptorjev beta za inhaliranje, modifikatorji levkotriena, teofilini in peroralnimi antihistaminiki.
English: Omalizumab binds to IgE and prevents binding of IgE to FcRI (high-affinity IgE receptor), thereby reducing the amount of free IgE that is available to trigger the allergic cascade.
Slovenian: Omalizumab se veže na IgE in preprečuje vezavo IgE na receptor FcRI (IgE receptor z veliko afiniteto), s čimer zmanjša količino prostega IgE, ki je na voljo za sprožanje alergijske kaskade.
English: Children (6 to 11 years of age) are not expected to self-administer Xolair.
Slovenian: Pri otrocih (ki so stari od 6 do 11 let) ni predvideno, da bi si zdravilo Xolair dajali sami.
English: Table 1 Conversion from dose to number of vials, number of injections and total injection volume for each administration
Slovenian: Preglednica 1 Preračunavanje odmerkov v število vial, število injekcij in celotni injicirani volumen za vsako apliciranje zdravila
English: Prescribing physicians should ensure that adult and adolescent patients with IgE below 76 IU/ml and children (6 to < 12 years of age) with IgE below 200 IU/ml have unequivocal in vitro reactivity (RAST) to a perennial allergen before starting therapy.
Slovenian: Zdravniki, ki predpisujejo zdravilo, se morajo pred začetkom zdravljenja prepričati, da imajo odrasli in adolescentni bolniki z IgE pod 76 i.e./ml ter otroci (stari 6 do <12 let) z IgE pod 200 i.e./ml nedvoumno in vitro reaktivnost (RAST) na trajno prisoten alergen.
English: After the medicine has been injected, the syringe guard will be activated to cover the needle.
Slovenian: Po injiciranju zdravila, se zapiralo brizge aktivira in pokrije iglo.
English: In these patients, physicians should be alert to the development of marked eosinophilia, vasculitic rash, worsening pulmonary symptoms, paranasal sinus abnormalities, cardiac complications, and/or neuropathy.
Slovenian: Pri teh bolnikih morajo biti zdravniki pozorni na pojavljanje izrazite eozinofilije, izpuščaja v povezavi z vaskulitisom, slabšanja pljučnih simptomov, bolezenskih sprememb v obnosnih votlinah, zapletov na srcu in/ali nevropatije.
English: In clinical studies in CSU patients, maximum suppression of free IgE was observed 3 days after the first subcutaneous dose.
Slovenian: V kliničnih študijah pri bolnikih s kronično spontano urtikarijo so največje znižanje ravni prostega IgE opažali 3 dni po prvem subkutanem odmerku.
English: Table 3 ADMINSTRATION EVERY 2 WEEKS.
Slovenian: Preglednica 3 APLIKACIJA VSAKA 2 TEDNA.
English: If it has expired, return the entire pack to the pharmacy.
Slovenian: Če se je rok uporabnosti iztekel, vrnite celotno pakiranje zdravila v lekarno.
English: In the final analysis of the observational study, the rate of ATE per 1,000 patient years was 7.52 (115/15,286 patient years) for Xolair-treated patients and 5.12 (51/9,963 patient years) for control patients.
Slovenian: Po rezultatih končne analize observacijske študije je bila pogostnost arterijskih trombemboličnih dogodkov na 1.000 bolnikov-let 7,52 (115/15.286 bolnikov-let) pri bolnikih, ki so prejemali zdravilo Xolair, in 5,12 (51/9.963 bolnikov-let) pri kontrolnih bolnikih.
English: A separate table (Table 5) shows the adverse reactions for the CSU indication resulting from differences in dosages and treatment populations (with significantly different risk factors, comorbidities, co-medications and ages [e.g. asthma trials included children from 6-12 years of age]).
Slovenian: V ločeni preglednici (preglednici 5) so prikazani neželeni učinki pri uporabi pri kronični spontani urtikariji, do katerih je prišlo zaradi razlik v odmerjanju in pri različnih študijskih populacijah (pri bolnikih z značilno različnimi dejavniki tveganja, sočasnimi boleznimi in sočasnimi zdravili ter različne starosti [npr. v preskušanja bolnikov z astmo so bili vključeni otroci v starosti 6-12 let]).
English: The population pharmacokinetics of omalizumab were analysed to evaluate the effects of demographic characteristics.
Slovenian: Analizirali so populacijsko farmakokinetiko omalizumaba, da bi ovrednotili učinke demografskih značilnosti.
English: P-value vs. placebo *Modified intent-to-treat (mITT) population: included all patients who were randomised and received at least one dose of study medication.
Slovenian: 95-odstotni interval zaupanja za razliko vrednost P za razliko v primerjavi z uporabo placeba *Modificirana populacija z namenom zdravljenja (angl. modified intent-to-treat population, mITT): vključuje vse bolnike, ki so bili randomizirani in so prejeli najmanj en odmerek študijskega zdravila.
English: Following doses of 75 mg, 150 mg or 300 mg every 4 weeks in patients with CSU, trough serum concentrations of omalizumab increased proportionally with the dose level.
Slovenian: Pri uporabi odmerkov 75 mg, 150 mg in 300 mg vsake 4 tedne pri bolnikih s kronično spontano urtikarijo so se najnižje koncentracije omalizumaba v serumu zvišale sorazmerno z višino odmerka.
English: If you think you may be allergic to any of the ingredients, tell your doctor as you should not use Xolair.
Slovenian: Če mislite, da bi lahko bili alergični na katero od sestavin zdravila, povejte zdravniku, saj v tem primeru ne smete uporabljati zdravila Xolair.
English: Pack containing one vial of powder for solution for injection and one ampoule of water for injections.
Slovenian: Škatla vsebuje eno vialo praška za raztopino za injiciranje in eno ampulo vode za injekcije.
English: In CSU patients, based on population pharmacokinetic simulations, omalizumab serum elimination half-life at steady state averaged 24 days and apparent clearance at steady state for a patient of 80 kg weight was 3.0 ml/kg/day.
Slovenian: Pri bolnikih s kronično spontano urtikarijo je po podatkih simulacij populacijske farmakokinetike povprečni razpolovni čas izločanja omalizumaba iz seruma v stanju dinamičnega ravnovesja znašal 24 dni, navidezni očistek v stanju dinamičnega ravnovesja pri bolniku s telesno maso 80 kg pa je znašal 3,0 ml/kg/dan.
English: The pharmacokinetics of omalizumab have been studied in adult and adolescent patients with allergic asthma.
Slovenian: Farmakokinetiko omalizumaba so proučevali pri odraslih in adolescentnih bolnikih z alergijsko astmo.
English: In studies 1 and 2, patients had a mean weekly itch severity score of between 13.7 and 14.5 at baseline and a mean UAS7 score of 29.5 and 31.7 respectively.
Slovenian: V študijah 1 in 2 so imeli bolniki ob izhodišču povprečno oceno srbenja v enem tednu med 13,7 in 14,5, povprečni oceni na lestvici UAS7 pa sta bili 29,5 oziroma 31,7.
English: Symptoms suggestive of serum sickness include arthritis/arthralgias, rash (urticaria or other forms), fever and lymphadenopathy.
Slovenian: Simptomi, ki nakazujejo možnost serumske bolezni, vključujejo artritis/artralgije, izpuščaj (urtikarijo ali druge oblike), zvišano telesno temperaturo in limfadenopatijo.
English: Xolair is not meant to prevent or treat other allergy-type conditions, such as sudden allergic reactions, hyperimmunoglobulin E syndrome (an inherited immune disorder), aspergillosis (a fungus-related lung disease), food allergy, eczema or hay fever because Xolair has not been studied in these conditions.
Slovenian: Zdravilo Xolair ni namenjeno preprečevanju ali zdravljenju drugih stanj alergijskega tipa, na primer nenadnih alergijskih reakcij, sindroma hiperimunoglobulina E (to je dedna imunska bolezen), aspergiloze (bolezen pljuč, povezana z glivicami), alergije na hrano, ekcema ali senenega nahoda, ker uporaba zdravila Xolair za zdravljenje teh bolezni ni proučena.
English: The adverse reactions are listed by MedDRA system organ class.
Slovenian: Neželeni učinki so navedeni po organskih sistemih v skladu s klasifikacijo MedDRA.
English: These analyses suggest that no dose adjustments are necessary in patients with CSU for age (12-75 years), race/ethnicity, gender, body weight, body mass index, baseline IgE, anti-FcRI autoantibodies or concomitant use of H2 antihistamines or LTRAs.
Slovenian: Rezultati teh analiz kažejo, da pri bolnikih s kronično spontano urtikarijo ni treba prilagajati odmerjanja zaradi starosti (12-75 let), rase/etnične pripadnosti, spola, telesne mase, indeksa telesne mase, izhodiščne koncentracije IgE, prisotnosti avtoprotiteles proti receptorjem FcRI ali sočasne uporabe zaviralcev histaminskih receptorjev H2 oziroma antagonistov levkotrienskih receptorjev.
English: Chronic administration of omalizumab at dose levels of up to 250 mg/kg (at least 14 times the highest recommended clinical dose in mg/kg according to the recommended dosing table) was well tolerated in non-human primates (both adult and juvenile animals), with the exception of a dose-related and agedependent decrease in blood platelets, with a greater sensitivity in juvenile animals.
Slovenian: Kronično uporabo omalizumaba v odmerkih do 250 mg/kg (kar je po tabeli priporočenega odmerjanja najmanj 14-kratnik najvišjega priporočenega kliničnega odmerka v mg/kg) so primati razen človeka (tako odrasle kot mlade živali) dobro prenašali, z izjemo zmanjšanja koncentracije trombocitov, ki je bilo odvisno od odmerka in povezano s starostjo, za katero so bile mlade živali občutljivejše.
English: Table 4 Adverse reactions
Slovenian: Preglednica 4 Neželene reakcije
English: Following multiple doses of omalizumab, areas under the serum concentration-time curve from Day 0 to Day 14 at steady state were up to 6-fold of those after the first dose.
Slovenian: Po več odmerkih omalizumaba so bile površine pod krivuljo serumska koncentracija-čas od dneva 0 do dneva 14 v stabilnem stanju do 6-krat večje od tistih po prvem odmerku.
English: The apparent volume of distribution in patients with asthma following subcutaneous administration was 78 ± 32 ml/kg.
Slovenian: Navidezni porazdelitveni prostor pri bolnikih z astmo po subkutani aplikaciji je bil 78 ± 32 ml/kg.
English: Table 7 Change from baseline to week 12 in weekly itch severity score, studies 1, 2 and 3 (mITT population*)
Slovenian: Preglednica 7 Sprememba ocene izraženosti srbenja v enem tednu od izhodišča do 12. tedna v študijah 1, 2 in 3 (populacija mITT*)
English: Holding the syringe horizontally, look into the viewing window to check the expiry date printed on the label.
Slovenian: Injekcijsko brizgo držite vodoravno in v preglednem okencu preverite datum izteka roka uporabnosti, ki je natisnjen na nalepki.
English: Maximum tolerated dose of Xolair has not been determined.
Slovenian: Največji odmerek zdravila Xolair, ki ga bolniki prenesejo, ni bil določen.
English: One year after discontinuation of Xolair dosing, the IgE levels had returned to pre-treatment levels with no observed rebound in IgE levels after washout of the medicinal product.
Slovenian: Eno leto po prekinitvi odmerjanja zdravila Xolair so se koncentracije IgE vrnile na vrednosti pred zdravljenjem, povratnega učinka zviševanja koncentracij IgE po popolni izločitvi zdravila pa niso opazili.
English: Analyses of these limited data suggest that no dose adjustments are necessary for age (6-76 years), race/ethnicity, gender or Body Mass Index (see section 4.2).
Slovenian: Analize teh omejenih podatkov kažejo, da zaradi starosti (6-76 let), rase/narodnosti, spola ali indeksa telesne mase odmerjanja ni treba prilagajati (glejte poglavje 4.2).
English: What you need to know before you are given Xolair
Slovenian: Kaj morate vedeti, preden boste prejeli zdravilo Xolair
English: If you think you may be allergic to any of the ingredients, tell your doctor as you should not be given Xolair.
Slovenian: Če mislite, da bi lahko bili alergični na katero od sestavin zdravila, povejte zdravniku, saj v tem primeru ne smete dobiti zdravila Xolair.
English: The efficacy and safety of Xolair were demonstrated in two randomised, placebo-controlled phase III studies (study 1 and 2) in patients with CSU who remained symptomatic despite H1 antihistamine therapy at the approved dose.
Slovenian: Varnost in učinkovitost zdravila Xolair so dokazali v dveh randomiziranih, s placebom kontroliranih študijah faze III (v študiji 1 in 2) pri bolnikih s kronično spontano urtikarijo, pri katerih so simptomi vztrajali kljub zdravljenju z zaviralci histaminskih receptorjev H1 v odobrenem odmerku.
English: Table 5 Adverse reactions from the pooled CSU safety database (day 1 to week 24) at 300 mg omalizumab
Slovenian: Preglednica 5 Neželeni učinki iz baze združenih varnostnih podatkov bolnikov s kronično spontano urtikarijo (od 1. dne do konca 24. tedna) pri uporabi 300 mg omalizumaba
English: What Xolair contains - The active substance is omalizumab.
Slovenian: Kaj vsebuje zdravilo Xolair - Učinkovina je omalizumab.
English: What you need to know before you use Xolair
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Xolair
English: Gently pinch the skin at the injection site and insert the needle as shown.
Slovenian: Na mestu injiciranja kožo nežno stisnite v gubo in zabodite iglo, kot kaže slika.
English: Posology The recommended dose is 300 mg by subcutaneous injection every four weeks.
Slovenian: Priporočeni odmerek je 300 mg s subkutano injekcijo vsake štiri tedne.
English: Antibodies to omalizumab have been detected in a low number of patients in clinical trials (see section 4.8).
Slovenian: V kliničnih preskušanjih so pri manjšem številu bolnikov odkrili protitelesa proti omalizumabu (glejte poglavje 4.8).
English: Since IgE may be involved in the immunological response to some helminth infections, Xolair may indirectly reduce the efficacy of medicinal products for the treatment of helminthic or other parasitic infections (see section 4.4).
Slovenian: Ker jeIgE lahko vpleten v imunski odziv na nekatere infestacije s helminti, lahko zdravilo Xolair posredno zmanjša učinkovitost zdravil za zdravljenje infestacij s helminti ali z drugimi paraziti (glejte poglavje 4.4).
English: After discontinuation of Xolair, free IgE levels increased towards pre-treatment levels over a 16-week treatment-free follow-up period.
Slovenian: Po prekinitvi odmerjanja zdravila Xolair se je v 16-tedenskem obdobju spremljanja brez zdravljenja raven prostega IgE zviševala proti vrednostim pred začetkom zdravljenja.
English: If a caregiver is giving the injection, the outer upper arms may also be used.
Slovenian: Če vam injekcijo daje negovalec, lahko zdravilo injicira tudi na zunanji strani nadlakti.
English: Following a single subcutaneous dose in adult and adolescent patients with asthma or CSU, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 6-8 days.
Slovenian: Po enem samem subkutanem odmerku pri odraslih in adolescentnih bolnikih z astmo ali s kronično spontano urtikarijo se je omalizumab absorbiral počasi in dosegel najvišje serumske koncentracije čez povprečno 6-8 dni.
English: In reproduction studies in cynomolgus monkeys, subcutaneous doses up to 75 mg/kg per week (at least 8 times the highest recommended clinical dose in mg/kg over a 4-week period) did not elicit maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis and did not elicit adverse effects on foetal or neonatal growth when administered throughout late gestation, delivery and nursing.
Slovenian: V študijah razmnoževanja na opicah cinomolgus subkutani odmerki do 75 mg/kg na teden (najmanj 8-kratnik najvišjega priporočenega kliničnega odmerka v mg/kg v 4-tedenskem obdobju) niso povzročali toksičnosti za mater, embriotoksičnosti ali teratogenosti, ko so jih aplicirali brejim opicam ves čas organogeneze, in niso povzročali neželenih učinkov na rast ploda ali novorojenčka, ko so jih aplicirali med pozno brejostjo, kotitvijo in dojenjem.
English: No natural rubber latex has to date been detected in the removable needle cap.
Slovenian: Do sedaj v snemljivem pokrovčku igle niso še nikoli našli samega naravnega lateksa.
English: Chronic spontaneous urticaria (CSU)
Slovenian: Kronična spontana urtikarija (CSU)
English: Omalizumab binds to IgE and prevents binding of IgE to FcRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade.
Slovenian: Omalizumab se veže na IgE in preprečuje vezavo IgE na receptor FcRI (IgE receptor z veliko afiniteto) na bazofilcih in mastocitih, s čimer zmanjša količino prostega IgE, ki je na voljo za sprožanje alergijske kaskade.
English: In a separate analysis of pooled clinical trials, which included all randomised double-blind, placebo-controlled clinical trials lasting 8 or more weeks, the rate of ATE per 1,000 patient years was 2.69 (5/1,856 patient years) for Xolair-treated patients and 2.38 (4/1,680 patient years) for placebo patients (rate ratio 1.13, 95% confidence interval 0.24-5.71).
Slovenian: Po rezultatih ločene analize združenih podatkov iz vseh randomiziranih, dvojno-slepih, s placebom kontroliranih kliničnih preskušanj, ki so trajala najmanj 8 tednov, je bila pogostnost arterijskih trombemboličnih dogodkov na 1.000 bolnikov-let 2,69 (5/1.856 bolnikov-let) pri bolnikih, ki so prejemali zdravilo Xolair, in 2,38 (4/1.680 bolnikov-let) pri bolnikih, ki so prejemali placebo, (razmerje pogostnosti 1,13, 95-odstotni interval zaupanja 0,24-5,71).
English: For all six studies there was a statistically significant improvement from baseline in quality of life scores for Xolair patients versus the placebo or control group.
Slovenian: V vseh šestih študijah so se rezultati ugotavljanja kvalitete življenja od izhodišča pri bolnikih, zdravljenih z zdravilom Xolair, statistično značilno izboljšali v primerjavi s skupino s placebom ali kontrolno skupino.
English: The efficacy and safety of Xolair were demonstrated in a 28-week double-blind placebo-controlled study (study 1) involving 419 severe allergic asthmatics, ages 12-79 years, who had reduced lung function (FEV1 40-80% predicted) and poor asthma symptom control despite receiving high dose inhaled corticosteroids and a long-acting beta2-agonist.
Slovenian: Učinkovitost in varnost zdravila Xolair so pokazali v 28-tedenski dvojno slepi, s placebom kontrolirani študiji (študija 1), ki je zajela 419 težkih bolnikov z alergijsko astmo, starih 12-79 let, ki so imeli zmanjšano funkcijo pljuč (FEV1 40-80 % pričakovane) in slabo obvladovanje simptomov astme, čeprav so jemali velike odmerke kortikosteroidov za inhaliranje in dolgotrajno delujoč agonist adrenergičnih receptorjev beta2.
English: • Store this medicine sealed in its outer box to protect it from light.
Slovenian: • Zdravilo shranjujte v originalno zaprti zunanji škatli za zagotovitev zaščite pred svetlobo.
English: Xolair therapy has not been studied in patients with autoimmune diseases, immune complex-mediated conditions, or pre-existing renal or hepatic impairment (see section 4.2).
Slovenian: Zdravljenja z zdravilom Xolair niso proučevali pri bolnikih z avtoimunskimi boleznimi, s stanji, v katere je vpleten imunski kompleks, ali z že obstoječimi okvarami ledvic ali jeter (glejte poglavje 4.2).
English: In all five studies a significantly greater proportion of Xolair treated patients were judged to have achieved either a marked improvement or complete control of their asthma compared to placebo patients.
Slovenian: V vseh petih študijah so ocenili, da je dosegel bodisi značilno izboljšanje bodisi popolno obvladanje astme značilno večji delež bolnikov, zdravljenih z zdravilom Xolair, kot bolnikov, ki so dobivali placebo.
English: Clinical efficacy and safety in chronic spontaneous urticaria (CSU)
Slovenian: Klinična učinkovitost in varnost pri kronični spontani urtikariji
English: In allergic asthma, the safety and efficacy of Xolair in paediatric patients below the age of 6 years have not been established.
Slovenian: Za uporabo pri alergijski astmi varnost in učinkovitost zdravila Xolair pri pediatričnih bolnikih, starih manj kot 6 let, nista bili dokazani.
English: However, if you are being treated for CSU, your doctor may stop Xolair treatment from time to time so that your symptoms can be assessed.
Slovenian: Če se zdravite zaradi kronične spontane urtikarije, vam bo zdravnik morda kljub temu od časa do časa prekinil zdravljenje z zdravilom Xolair, da bo lahko ocenil vaše simptome.